As. Pelkonen et al., EFFECT OF NEONATAL SURFACTANT THERAPY ON LUNG-FUNCTION AT SCHOOL-AGE IN CHILDREN BORN VERY PRETERM, Pediatric pulmonology, 25(3), 1998, pp. 182-190
Our aim was to evaluate long-term effects of exogenous surfactant ther
apy on pulmonary functional outcome in children born very preterm. We
examined 40 children aged 7-12 years who were born before 30 weeks of
gestation with an immature surfactant system, and were randomized to o
ne of three treatment groups: human surfactant given at birth (prophyl
actic), human surfactant given after development of neonatal respirato
ry distress syndrome (rescue), and placebo (air) treatment. Spirometri
c parameters of preterm born children were compared with those of 20 c
hildren born at term. In addition, spirometric parameters were monitor
ed twice daily for 4 weeks using a home spirometer. All spirometric pa
rameters were significantly lower in the preterm groups than in the co
ntrols, except for the forced vital capacity (FVC) in the prophylactic
ally treated group. Bronchial obstruction was found in 53% of the prop
hylactically treated group, in 36% of the rescue group, in 67% of the
placebo group, and in 0% of the control group. Peak expiratory flow (P
EF) and FVC values were higher in those children who received surfacta
nt compared with the placebo group (P < 0.05). In 16 children (40%) bo
rn preterm, a beta(2)-agonist induced an increase in PEF greater than
or equal to 15% at least three times during 2 weeks of home monitoring
; eight children (20%) had abnormal diurnal PEF variation. Multiple re
gression analysis indicated that the independent variables associated
with favorable outcomes in spirometric parameters were surfactant ther
apy (P = 0.012-0.045) and short intubation time after birth (P = 0.000
9-0.0044). Bronchial obstruction, responsiveness to a beta(2)-agonist,
and high diurnal PEF variation are common in children born before 30
gestational weeks. Surfactant supplementation reducing the need for me
chanical ventilation or supplementary oxygen after birth may decrease
the severity of immaturity related bronchial obstruction in childhood.
(C) 1998 Wiley-Liss, Inc.